{"nctId":"NCT02308046","briefTitle":"Multi-Center Study of New Medications to Treat Vaginal Infections","startDateStruct":{"date":"2015-06","type":"ACTUAL"},"conditions":["Vaginal Infection"],"count":212,"armGroups":[{"label":"Terconazole vaginal gel","type":"ACTIVE_COMPARATOR","interventionNames":["Drug: Terconazole"]},{"label":"Gel vehicle","type":"PLACEBO_COMPARATOR","interventionNames":["Drug: Placebo"]}],"interventions":[{"name":"Terconazole","otherNames":[]},{"name":"Placebo","otherNames":[]}],"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* A clinical diagnosis of vaginal infection that is confirmed by laboratory testing and:\n* Capable of providing written informed consent or assent\n* Currently not menstruating and not anticipating menses during treatment\n* If heterosexually active, subject must be post-menopausal for â‰¥ 1 year, surgically sterile, or practicing an acceptable form of birth control\n* Negative pregnancy test\n* Other criteria as identified in the protocol\n\nExclusion Criteria:\n\n* Other infectious causes of vulvovaginitis\n* Subject has recently used, or is expected to require the concomitant use of prohibited medications/products\n* Nursing mother\n* Use of any investigational drug within 30 days of enrollment\n* History of hypersensitivity to any ingredient/component of the formulations\n* Other criteria as identified in the protocol","healthyVolunteers":false,"sex":"FEMALE","minimumAge":"12 Years","stdAges":["CHILD","ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Clinical Cure as Assessed by the Investigator at the Test-of-cure Visit","description":"The percentage of participants with clinical cure in each arm was compared. A clinical cure is defined as the resolution of all signs and symptoms attributable to vulvovaginal candidiasis","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"47","spread":null},{"groupId":"OG001","value":"25","spread":null}]}]}]},{"type":"SECONDARY","title":"Improvement/Cure of Individual and Cumulative Signs, Symptoms and Criteria for the Infection","description":"Signs (edema, erythema, excoriation) and symptoms (itching, burning irritation) were each scored as absent (0), mild (1), moderate (2) or severe (3). A total sign score of 0-9 and total symptom score of 0-9 were combined for a total possible combined sign and symptom score of 0-18. Total median combined sign and symptom severity score was compared between arms at the test of cure visit. Lower scores at day 7-14 indicate improvement.","paramType":"MEDIAN","dispersionType":"Full Range","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"0.0","spread":null},{"groupId":"OG001","value":"3.0","spread":null}]}]}]},{"type":"SECONDARY","title":"Mycologic Cure","description":"Vaginal swabs were cultured for Candida species in a laboratory. A positive culture indicates presence of vaginal yeast and a negative culture indicates absence of vaginal yeast. A negative culture indicates mycologic cure.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"57","spread":null},{"groupId":"OG001","value":"6","spread":null}]},{"measurements":[{"groupId":"OG000","value":"13","spread":null},{"groupId":"OG001","value":"54","spread":null}]},{"measurements":[{"groupId":"OG000","value":"3","spread":null},{"groupId":"OG001","value":"7","spread":null}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"31","spread":null},{"groupId":"OG001","value":"7","spread":null}]},{"measurements":[{"groupId":"OG000","value":"24","spread":null},{"groupId":"OG001","value":"30","spread":null}]},{"measurements":[{"groupId":"OG000","value":"18","spread":null},{"groupId":"OG001","value":"30","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants Reporting Complete Resolution of Symptoms by Test of Cure Visit","description":"Subjects reported if symptoms completely resolved and the date of resolution. The percentage of participants reporting complete resolution of symptoms was compared between arms.","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"45","spread":null},{"groupId":"OG001","value":"29","spread":null}]}]}]},{"type":"SECONDARY","title":"Number of Participants With Treatment Emergent Adverse Events","description":"Adverse events were collected at study visits, from subject diaries and from spontaneous reports","paramType":"COUNT_OF_PARTICIPANTS","dispersionType":null,"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"39","spread":null},{"groupId":"OG001","value":"38","spread":null}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":0,"n":102},"commonTop":["Bacterial vaginosis","Vulvovaginal burning sensation"]}}}